血清脂蛋白a、脂蛋白相关磷脂酶A2与代谢综合征合并缺血性脑卒中静脉溶栓患者临床预后的相关性分析

doi:10.20047/j.issn1673-7210.2023.35.20

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (749 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the correlation between serum lipoprotein a (Lp[a]), lipoprotein-associated phospholipase A2 (LP-PLA2), and clinical prognosis in patients with metabolic syndrome complicated with ischemic stroke treated with intravenous thrombolytic therapy. Methods A total of 107 patients with metabolic syndrome combined with hyperacute ischemic stroke admitted to Linfen Central Hospital of Shanxi Province from January 2020 to March 2022 were selected as the study objects. All patients received intravenous thrombolytic therapy with Alteplase after completing routine examination. Clinical data and Lp[a] and LP-PLA2 tests were collected. According to the changes of the National Institutes of Health stroke scale at admission and seven days after admission, the patients were divided into a recent improvement group (67 cases) and a recent no improvement group (40 cases), and according to the changes of the modified Rankin scale score at admission and 90 days after admission, the patients were divided into a long-term improvement group (72 cases) and a long-term no improvement group (35 cases). The clinical data and the differences of Lp[a] and LP-PLA2 were compared respectively, and the influencing factors of recent and long-term prognosis were analyzed, and the predictive value of the influencing factors was further analyzed. Results The levels of total cholesterol, triglyceride, low density lipoprotein, Lp[a], and LP-PLA2 in recent no improvement group were higher than those in recent improvement group (P＜0.05). The levels of total cholesterol, low density lipoprotein, Lp[a], and LP-PLA2 in the long-term no improvement group were higher than those in the long-term improvement group (P＜0.05). Logistic regression analysis showed that low-density lipoprotein (OR=1.073, 95%CI: 1.011-1.734), Lp[a] (OR=1.833, 95%CI: 1.631-2.341), LP-PLA2 (OR=1.725, 95%CI: 1.237-2.113) were the influencing factors of recent prognosis in patients with metabolic syndrome complicated with ischemic stroke treated with intravenous thrombolytic therapy (P＜0.05); Lp[a] (OR=1.743, 95%CI: 1.531-2.293), and LP-PLA2 (OR=1.685, 95%CI: 1.106-2.131) were the factors influencing the long-term prognosis of patients with metabolic syndrome complicated with ischemic stroke treated with intravenous thrombolytic therapy (P＜ 0.05). Lp[a] and LP-PLA2 could predict the recent and long-term prognosis of patients with metabolic syndrome complicated with ischemic stroke (P＜0.05). Conclusion Serum Lp[a] and LP-PLA2 levels in patients with metabolic syndrome complicated with intravenous thrombolysis of ischemic stroke have an influence on the near and long term prognosis, and have a certain prognostic value, which is worthy of attention in clinical work.

Key words： Lipoprotein a Lipoprotein-associated phospholipase A2 Metabolic syndrome Ischaemic stroke Intravenous thrombolytic therapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Yanli ZHAO Xiaodong LIANG Hui PEI Jinrui ZHOU Haimin LI Wanying

Cite this article:

CHEN Yanli ZHAO Xiaodong LIANG Hui PEI Jinrui ZHOU Haimin LI Wanying. Correlation analysis of serum lipoprotein a, lipoprotein-associated phospholipase A2, and clinical prognosis in patients with metabolic syndrome complicated with ischemic stroke treated with intravenous thrombolytic therapy[J]. 中国医药导报, 2023, 20(35): 92-97.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.35.20 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I35/92

[1] 王紫晨，马丽娜，张仲迎，等.代谢综合征对老年女性缺血性脑卒中患者预后的影响[J].中华老年心脑血管病杂志，2021，23（8）：846-849.
[2] Bas DF，Ozdemir AO. The effect of metabolic syndrome and obesity on outcomes of acute ischemic stroke patients treated with systemic thrombolysis [J]. J Neurol Sci，2017，383：1-4.
[3] 董芳，杜怡峰.代谢综合征与老年缺血性脑卒中继发血管性认知功能障碍的相关性分析[J].中国现代医学杂志，2017，27（27）：71-76.
[4] Koh MY，Toh KZ，Ho JS，et al. Intravenous thrombolysis and endovascular thrombectomy for acute ischaemic stroke in patients with Moyamoya disease-a systematic review and meta- summary of case reports [J]. J Thromb Thrombolysis，2022， 54（2）：339-349.
[5] Arenillas JF，Ispierto L，Millán M，et al. Metabolic syndrome and resistance to Ⅳ thrombolysis in middle cerebral artery ischemic stroke [J]. Neurology，2008，71（3）：190-195.
[6] 梁晨，倪贵华，尹红军，等.代谢综合征与缺血性脑卒中患者转归不良的相关性研究[J].临床神经病学杂志，2017，30（5）：346-349.
[7] 刘川，冯明，方向华，等.代谢综合征在缺血性卒中患者心脑血管事件发生中的作用[J].中华心血管病杂志，2011， 39（4）：358-362.
[8] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2017年版）[J].中华糖尿病杂志，2018，10（1）：4-67.
[9] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国各类主要脑血管病诊断要点2019[J].中华神经科杂志，2019，52（9）：710-715.
[10] Kasner SE. Clinical interpretation and use of stroke scales [J]. Lancet Neurol，2006，5（7）：603-612.
[11] 卢颖瑜，黄秉文，王金良，等.代谢综合征对急性缺血性脑卒中患者复发、死亡及生活依赖程度的影响[J].广西医学，2017，39（6）：799-802.
[12] 许磊.代谢综合征与其组分在缺血性脑卒中患者中的改变[J].中国实用神经疾病杂志，2016，19（14）：47-48.
[13] 邹莉，孟祥武.缺血性脑卒中可预防性危险因素的研究进展[J].实用心脑肺血管病杂志，2019，27（11）：98-101， 106.
[14] Li H，Khan S，Siddique R，et al. Obesity in acute ischaemic stroke patients treated with intravenous thrombolysis therapy [J]. Neurol Res，2021：1-8.
[15] Sobolewski P，Brola W，Szczuchniak W，et al. Intravenous Thrombolysis with Recombinant Tissue-type Plasminogen Activator for Acute Ischemic Stroke in Patients with Metabolic Syndrome [J]. J Stroke Cerebrovasc Dis，2015，24（8）：1787-1792.
[16] 滕秋玉.缺血性脑卒中合并代谢综合征的危险因素分析[J].中国冶金工业医学杂志，2020，37（6）：627-629.
[17] Langsted A，Nordestgaard BG，Kamstrup PR. Elevated Lip- oprotein（a）and Risk of Ischemic Stroke [J]. J Am Coll Cardiol，2019，74（1）：54-66.
[18] Vanacker P，Heldner MR，Seiffge D，et al. ASTRAL-R score predicts non-recanalisation after intravenous thrombolysis in acute ischaemic stroke [J]. Thromb Haemost，2015，113（5）：1121-1126.
[19] 北京心脏学会.脂蛋白（a）与心血管疾病风险关系及临床管理的专家科学建议[J].中国循环杂志，2021，36（12）：1158-1167.
[20] Morelli N，Rota E，Michieletti E，et al. Mechanical thrombectomy after intravenous thrombolysis for acute ischaemic stroke [J]. Lancet Neurol，2017，16（2）：103-104.
[21] Lin J，Zheng H，Cucchiara BL，et al. Association of Lp- PLA2-A and early recurrence of vascular events after TIA and minor stroke [J]. Neurology，2015，85（18）：1585-1591.
[22] Del Bene A，Palumbo V，Lamassa M，et al. Progressive lacunar stroke：review of mechanisms，prognostic features，and putative treatments [J]. Int J Stroke，2012，7（4）：321- 329.
[23] Sui Y，Luo J，Dong C，et al. Implementation of regional Acute Stroke Care Map increases thrombolysis rates for acute ischaemic stroke in Chinese urban area in only 3 months [J]. Stroke Vasc Neurol，2021，6（1）：87-94.
[24] Dorado L，Arenillas JF，López-Cancio E，et al. Metabolic Syndrome Predicts Refractoriness to Intravenous Thrombolysis in Acute Ischemic Stroke [J]. J Stroke Cerebrovasc Dis，2015，24（11）：2605-2612.
[25] Al-Kuraishy HM，Hussien NR，Al-Naimi MS，et al. Statins Therapy Improves Acute Ischemic Stroke in Patients with Cardio-metabolic Disorders Measured by Lipoprotein-Associated Phospholipase A2（Lp-PLA2）：New Focal Point [J]. Neurol India，2021，69（6）：1637-1644.
[26] Dorňák T，Sedlá■ková Z，■ivrn?伥 J，et al. Brain Imaging Fin- dings and Response to Intravenous Thrombolysis in Posterior Circulation Stroke [J]. Adv Ther，2021，38（1）：627- 639.